News | February 05, 2022
IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
It will be marketed under the brand name Molunamax
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Subscribe To Our Newsletter & Stay Updated
